Oncolytics Biotech® Reports 2018 Third Quarter Financial Results and Provides Corporate Update

– Checkpoint combination studies support progression into registration pathway for metastatic breast cancer and potential expansion of indications –

– Management to host webcast and conference call today at 8:30 a.m. ET –

CALGARY, Alberta and SAN DIEGO, Nov. 12, 2018 (GLOBE NEWSWIRE) — Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced financial results and operational highlights for the quarter ended September 30, 2018. All dollar amounts are Canadian unless otherwise noted.

“The clinical progress and mechanistic understandings achieved with pelareorep thus far in 2018 lay the ground work for a transformational 2019.  We continue to advance towards a registration study in metastatic breast cancer as we prepare to initiate our AWARE-1 window of opportunity clinical study with pelareorep and Roche’s checkpoint inhibitor, Tecentriq, in breast cancer patients,” said Dr. Matt Coffey, President and CEO of Oncolytics Biotech. “Although we originally believed that pelareorep acts foremost as a lytic agent directly killing tumor cells, we have learned pelareorep replicates efficiently in cancer cells to produce double stranded RNA and trigger an immune response to the tumor by stimulating and recruiting NK cells and T cells to target the tumor. This quarter we presented additional data confirming pelareorep stimulates expression of PD-L1 on tumor cells, thereby transforming those tumor cells into targets for the highly valued immuno-oncology checkpoint inhibitors.  This expanded focus on innate and adaptive immune response better allows us to prepare for our planned studies in metastatic breast cancer, to validate recently identified therapeutic biomarkers for pelareorep, and to efficiently explore the potential for pelareorep to extend the effectiveness of checkpoint inhibitors into additional patient  populations.”

Selected highlights since July 1, 2018

Clinical Updates

  • Established plans with pelareorep to advance the phase 3 metastatic breast cancer program and for expansion into combination trials with checkpoint inhibitors to  enlist pelareorep’s immune effects and to seek validation of key therapeutic and prognostic biomarkers.
  • Clinical trials announced in 2018 include:
      °  AWARE-1 window of opportunity (WOO) study with pelareorep in combination with Roche’s Tecentriq® in breast cancer.
      °  Pelareorep plus Merck’s anti-PD-1 checkpoint inhibitor Keytruda® in pancreatic cancer.
      °  Pelareorep plus Bristol-Myers Squibb’s anti-PD-1 checkpoint inhibitor Opdivo® in multiple myeloma.
      °  Pelareorep plus Merck’s anti-PD-1 checkpoint inhibitor Keytruda in multiple myeloma.
  • Announced a Master Clinical Supply Agreement with F. Hoffmann-La Roche Ltd (Roche) to supply Tecentriq for use in the company’s clinical development program.
  • Presented positive phase 2 clinical trial results for pelareorep in the treatment of patients with KRAS mutant metastatic colorectal cancer at the European Society for Medical Oncology (ESMO) 2018 Congress. Thirty-six patients received treatment with FOLFIRI/B (irinotecan, fluorouracil, leucovorin, plus bevacizumab) and pelareorep.  The six patients receiving treatment with the recommended study dose had progression free survival of 65.6 weeks and an overall survival of 107.5 weeks. Study results exceeded expectations when compared to analogous historical data.
  • Announced a publication demonstrating that intravenously delivered oncolytic viruses, including pelareorep, effectively target tumors even in the presence of neutralizing antibodies. A publication in Cancer Immunology Research showed that pelareorep, a systemically delivered oncolytic reovirus, can destroy tumor cells via a monocyte-mediated process even after the virions have been exposed to antibodies designed to neutralize the reovirus.

Corporate Updates

  • Entered into a common stock purchase agreement for up to US$26.0 million with Lincoln Park Capital Fund, LLC.
  • Announced a US$30.0 million At-the-Market facility with Canaccord Genuity.

Anticipated Milestones

  • Initiate a phase 2 study with pelareorep in combination with Merck’s Keytruda in advanced pancreatic cancer in Q4 2018*.
  • Initiate a phase 1 study with pelareorep in combination with Bristol-Myers Squibb’s Opdivo in multiple myeloma in Q4 2018*.
  • Initiate AWARE-1, a phase 1b WOO study with pelareorep in the neoadjuvant breast cancer setting in Q1 2019.
  • Initiate a phase 1b study with pelareorep in combination with Merck’s Keytruda in multiple myeloma in Q1 2019*.
  • Data from AWARE-1 study with pelareorep in breast cancer mid-2019.         
  • Initiate registration study with pelareorep in mBC – guidance to be provided after AWARE-1 data is available.
  • Preliminary data from MUK eleven study with pelareorep in multiple myeloma mid-2019*. 

* Guidance provided by principle investigator


  • At September 30, 2018, the company reported $16.2 million in cash and cash equivalents.
  • As at November 8, 2018, the company had an unlimited number of authorized common shares with 17,059,123 common shares issued and outstanding, 16,443,500 warrants exercisable into 1,730,894 common shares with a $9.025 strike price and 1,093,407 options and share units.
  • Operating expense for the third quarter of 2018 was $1.5 million compared to $1.3 million for the prior year period. R&D expense in the third quarter 2018 was $1.9 compared to $1.7 million for the third quarter of 2017.
  • The net loss for the third quarter of 2018 was $3.3 million or $0.20 per share compared to a net loss of $3.0 million or $0.20 per share for the period one year ago, on a consolidated basis. 

Webcast and Conference Call
Oncolytics management will host a conference call for Analysts and Institutional Investors at 8:30 a.m. ET today, Monday, November 12, 2018. The live call may be accessed by dialing (888) 231-8191 for callers in North America.  Overseas callers should contact investor relations for the toll-free dial information for their country.  A replay of this call will be available approximately two hours after the call is ended at 855-859-2056, using the replay code 6463668 and will be available for six months. 

A live audio webcast of the call will be accessible on the Investor Relations page of Oncolytics’ website at www.oncolyticsbiotech.com and will be archived for six months.

As at September 30,
December 31,
Current assets    
Cash and cash equivalents 16,214,347   11,836,119  
Contract receivable   4,767,100  
Other receivables 56,895   37,726  
Prepaid expenses 1,450,030   1,176,063  
Total current assets 17,721,272   17,817,008  
Non-current assets    
Property and equipment 428,588   333,441  
Total non-current assets 428,588   333,441  
Total assets 18,149,860   18,150,449  
Liabilities And Shareholders’ Equity    
Current Liabilities    
Accounts payable and accrued liabilities 2,239,514   3,684,023  
Contract liability 927,400   1,545,645  
Other liabilities 76,529    
Total current liabilities 3,243,443   5,229,668  
Non-current liabilities    
Contract liability 5,802,887   4,636,935  
Other liabilities 54,128    
Total non-current liabilities 5,857,015   4,636,935  
Total liabilities 9,100,458   9,866,603  
Shareholders’ equity    
Share capital
  Authorized: unlimited
  September 30, 2018 – 16,915,325
  December 31, 2017 – 141,805,722 pre-consolidation
  December 31, 2017 – 14,926,840 post-consolidation
283,742,409   271,710,138  
Warrants 3,617,570   3,617,900  
Contributed surplus 27,894,420   27,028,238  
Accumulated other comprehensive income 459,142   373,730  
Accumulated deficit (306,664,139 ) (294,446,160 )
Total shareholders’ equity 9,049,402   8,283,846  
Total liabilities and equity 18,149,860   18,150,449  

  Three Month
30, 2018
Three Month
30, 2017
Nine Month
30, 2018
Nine Month
30, 2017
Research and development 1,929,405   1,726,726   6,909,713   6,913,470  
Operating 1,468,262   1,309,607   4,869,617   4,054,450  
Loss before the following (3,397,667 ) (3,036,333 ) (11,779,330 ) (10,967,920 )
Interest 61,880   31,759   109,308   96,637  
Loss before income taxes (3,335,787 ) (3,004,574 ) (11,670,022 ) (10,871,283 )
Income tax (expense) recovery (79 ) 168   (547,957 ) 16  
Net loss (3,335,866 ) (3,004,406 ) (12,217,979 ) (10,871,267 )
Other comprehensive (loss) income items that may be reclassified to net loss        
Translation adjustment (49,238 ) (126,846 ) 85,412   (192,334 )
Net comprehensive loss (3,385,104 ) (3,131,252 ) (12,132,567 ) (11,063,601 )
Basic and diluted loss per common share (0.20 ) (0.20 ) (0.78 ) (0.80 )
Weighted average number of shares (basic and diluted) 16,540,612   14,685,871   15,646,117   13,625,411  

  Share Capital



As at December 31, 2016 262,321,825     26,643,044   554,060   (278,829,309 ) 10,689,620  
Net loss and other comprehensive loss       (192,334 ) (10,871,267 ) (11,063,601 )
Issued pursuant to “At the Market” agreement 1,479,065           1,479,065  
Issued pursuant to public offering 7,893,600   3,617,900         11,511,500  
Issued pursuant to stock option plan 536,949     (193,509 )     343,440  
Share based compensation     438,044       438,044  
Share issue costs (1,331,770 )         (1,331,770 )
As at September 30, 2017 270,899,669   3,617,900   26,887,579   361,726   (289,700,576 ) 12,066,298  
As at December 31, 2017 271,710,138   3,617,900   27,028,238   373,730   (294,446,160 ) 8,283,846  
Net loss and other comprehensive income       85,412   (12,217,979 ) (12,132,567 )
Issued pursuant to “At the Market” agreement 553,650           553,650  
Issued pursuant to public offering 11,606,882           11,606,882  
Issued pursuant to Common Stock Purchase Agreement 1,906,152           1,906,152  
Issued pursuant to stock option plan 178,322     (66,635 )     111,687  
Issued pursuant to warrant agreement 1,747   (330 )       1,417  
Share based compensation     932,817       932,817  
Share issue costs (2,214,482 )         (2,214,482 )
As at September 30, 2018 283,742,409   3,617,570   27,894,420   459,142   (306,664,139 ) 9,049,402  

  Three Month
30, 2018
Three Month
30, 2017
Nine Month
30, 2018
Nine Month
30, 2017
Operating Activities        
Net loss for the period (3,335,866 ) (3,004,406 ) (12,217,979 ) (10,871,267 )
Depreciation – property and equipment 26,698   20,591   67,682   70,315  
Share based compensation 236,607   148,447   932,817   438,044  
Unrealized foreign exchange loss (gain) 82,643   (6,414 ) (19,702 ) (119,058 )
Onerous lease contract 67,588     67,588    
Amortization – lease incentive liability 12,494     12,494    
Net change in non-cash working capital (596,779 ) (331,590 ) 3,630,991   (1,186,142 )
Cash used in operating activities (3,506,615 ) (3,173,372 ) (7,526,109 ) (11,668,108 )
Investing Activities        
Acquisition of property and equipment (40,094 ) (9,451 ) (120,156 ) (95,337 )
Redemption of short-term investments       2,088,800  
Cash (used in) provided by investing activities (40,094 ) (9,451 ) (120,156 ) 1,993,463  
Financing Activities        
Proceeds from “At the Market” equity distribution agreement   733,171   520,315   1,292,698  
Proceeds from public offering     10,188,526   10,366,098  
Proceeds from Common Stock Purchase Agreement 1,143,361     1,143,361    
Proceeds from exercise of options 87,777   48,090   111,687   343,440  
Proceeds from exercise of warrants     1,417    
Cash provided by financing activities 1,231,138   781,261   11,965,306   12,002,236  
(Decrease) increase in cash (2,315,571 ) (2,401,562 ) 4,319,041   2,327,591  
Cash and cash equivalents, beginning of period 18,741,347   16,676,298   11,836,119   12,034,282  
Impact of foreign exchange on cash and cash equivalents (211,429 ) (241,092 ) 59,187   (328,229 )
Cash and cash equivalents, end of period 16,214,347   14,033,644   16,214,347   14,033,644  

To view the Company’s Fiscal 2018 Third Quarter Consolidated Financial Statements, related Notes to the Consolidated Financial Statements, and Management’s Discussion and Analysis, please see the Company’s filings, which will be available at www.sedar.com, www.sec.gov and on Oncolytics’ website at http://www.oncolyticsbiotech.com/investor-centre/financials/.

About Pelareorep
Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus: a first-in-class intravenously delivered immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses to treat a variety of cancers and has been demonstrated to be able to escape neutralizing antibodies found in patients.

About Oncolytics Biotech Inc.
Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype — turning “cold” tumors “hot” — through innate and adaptive immune responses to treat a variety of cancers. Oncolytics’ clinical development program emphasizes three pillars: chemotherapy combinations to trigger selective tumor lysis and immuno-therapy and immune modulator (IMiD) combinations to produce innate and adaptive immune responses. Oncolytics is currently conducting and planning additional studies in combination with checkpoint inhibitors and targeted and IMiD therapies in solid and hematological malignancies, as it prepares for a phase 3 registration study in metastatic breast cancer. For further information, please visit: www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as “forward-looking statements”). Forward-looking statements, including the Company’s belief as to the potential and mode of action of REOLYSIN, also known as pelareorep, as a cancer therapeutic; the collaboration between Merck and USC using pelareorep, including the  timing, enrollment and potential benefits to the Company thereof; and other statements related to anticipated developments in the Company’s business and technologies involve known and unknown risks and uncertainties, which could cause the Company’s actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, the Company’s ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company’s quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.

Company Contact
Michael Moore
Vice President, Investor Relations & Corporate Communications
Investor Relations
Robert Uhl
Westwicke Partners
Media Contact
Jason Spark
Canale Communications 

Oncolytics Biotech.jpg

Source: Oncolytics Biotech, Inc.